Natco Pharma launches tablets to treat pulmonary arterial hypertension

Natco Pharma on Wednesday, August 20, announced it has launched oral suspension tablets used in the treatment of pulmonary arterial hypertension (PAH).

In an exchange filing, the company said it has launched Bosentan tablets for oral suspension (TFOS), 32mg, a generic version of Tracleer by Actelion Pharmaceuticals US Inc. NATCO’s marketing partner for the product is Lupin Ltd.

The company added that it holds the first-to-file status for this product and will have 180-day generic drug exclusivity.

Bosentan tablets are used for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in paediatric patients aged three years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability.

The drug has an estimated sales of $10 million in the US for the 12 months ending June 2025 as per industry sales data.

Natco Pharma reported its first quarter earnings last week. Its consolidated net profit declined to ₹480 crore in the June quarter from ₹668.5 crore in the previous year.

Its revenue declined 2.5% to ₹1,329 crore while its EBITDA dropped 32% to ₹519 crore from ₹764.9 crore last eyar.

Its operating margins contracted to 39% from 56.1% in the year-ago period. 

Natco Pharma shares were down 0.6% at ₹887.3 apiece at 12.45 pm on Wednesday. The stock has declined 36.5% this year, so far.

Also Read: Nazara Tech shares fall 6% after online gaming bill clears; PL sees sharp cuts to target